The decision follows a similar one in the US and is due to the drug's failure to significantly improve overall survival versus chemo in the TROPION-Lung01 trial.

After unusual symptoms forced him to retire from his job, Gerardo Bada was diagnosed with lung cancer after visiting the ...

Imfinzi reduced risk of death by 27% and reduced disease progression by 24% compared to patients receiving a placebo. 2. In ...

Rigel Pharmaceuticals has shown significant growth, particularly from the acquisition of pralsetinib. Read why RIGL stock is ...

H.C. Wainwright initiated coverage of Nuvalent (NUVL) with a Buy rating and $110 price target Nuvalent is a clinical stage biotechnology ...

From the benefits of early adoption to the effectiveness of telehealth, here is what we reported about palliative care ...

Individualized cancer vaccines and antibody-drug conjugates will be among the dominant biotech innovations in cancer next ...

Artificial intelligence (AI)-aided analysis of pathology slides showed potential as a predictive biomarker for non-small cell ...

Opdivo Qvantig is approved for solid tumors, including melanoma, renal cell carcinoma, and non-small cell lung cancer. The ...

Immunotherapy has transformed cancer treatment, offering new avenues of hope for patients with advanced disease or limited ...

Sino Biopharmaceutical (HK:1177) has released an update.Don't Miss Our Christmas Offers:Discover the latest stocks recommended by top Wall ...

There is plenty to like about Merck ( MRK -0.17%). It is one of the largest pharmaceutical companies and the owner of the ...